lorlatinib - Robuta Search

https://adisinsight.springer.com/drugsafety/803895458?error=cookies_not_supported&code=3be93116-3575-46d1-83ec-486d09a8b294 Lorlatinib, risk of metabolic adverse events - AdisInsight Lorlatinib use is associated with a variety of metabolic adverse events, particularly those related to lipid metabolism and weight changes.This is the main adverse events lorlatinib risk metabolic adisinsight https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-lorlatinib-for-advanced-non-small-cell-lung-cancer-alkaline A study looking at lorlatinib for advanced non small cell lung cancer (ALKALINE) This study is looking at lorlatinib for non small cell lung cancer that has a change (mutation) in the anaplastic lymphoma kinase (ALK) gene. small cell lung cancer https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lorlatinib Definition of lorlatinib - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... definition of lorlatinib nci drug dictionary https://adisinsight.springer.com/drugsafety/803923376?error=cookies_not_supported&code=cb7078f9-a0cf-4225-bf2f-4cfb045fa8e9 Batoprotafib/Binimetinib/Lorlatinib - AdisInsight Seventeen patients with ALK- or ROS1-rearranged non-small cell lung cancer (NSCLC) who had previously progressed on ALK or ROS1 inhibitors received lorlatinib binimetinib lorlatinib adisinsight https://www.med.cuhk.edu.hk/press-releases/cuhk-co-leads-global-lung-cancer-study-supporting-lorlatinib-as-first-line-treatment-option-for-alk-positive-advanced-nsclc-patients CUHK co-leads global lung cancer study Supporting lorlatinib as first-line treatment option for... Professor Tony Mok Shu-kam from CU Medicine and several other international lung cancer experts joined forces to co-lead a Phase III trial for patients with... https://myhealth.alberta.ca/Health/medications/Pages/conditions.aspx?hwid=fdb1976 Lorlatinib - Oral lorlatinib oral https://www.nice.org.uk/guidance/TA628 Overview | Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |... Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults https://pubmed.ncbi.nlm.nih.gov/38149055/ Case report: SAF-189s is a potent inhibitor in a lorlatinib-resistant NSCLC patient with acquired... Acquired anaplastic lymphoma kinase (ALK) mutation is the major resistant mechanism to ALK tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer... https://adisinsight.springer.com/drugsafety/803927323?error=cookies_not_supported&code=260f06df-aa19-4269-8a53-2ef0c652c5df Naxitamab/Lorlatinib - AdisInsight A 12-year-old patient with refractory high-risk stage M neuroblastoma and persistent bone and bone marrow involvement experienced hypotension, abdominal pain naxitamab lorlatinib adisinsight https://pubmed.ncbi.nlm.nih.gov/41323056/ A Rare Case of Hemolytic Anemia after Alectinib That Did Not Recur after Switching to Lorlatinib This is the first report describing a rapid increase in hemoglobin after pausing alectinib and no relapse of hemolysis after switching to lorlatinib, while the... https://pubmed.ncbi.nlm.nih.gov/33685866/ Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung...